Clinical trials: Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer, Pancreatic Cancer
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to…
- Trial name
- NCT04117087
- Testing
- KRAS peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Daraxonrasib in Resectable PDAC
This Phase 1 interventional treatment study is evaluating oral daraxonrasib in participants with resectable pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07898813
- Testing
- Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07769502
- Testing
- Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas
Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Intraepithelial Neoplasia
- Trial name
- B-PDAC (NCT07709052)
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Resectable Pancreatic Ductal Adenocarcinoma
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma
This is a single arm, non-randomized phase II study of neoadjuvant metformin in resectable PDAC. Twenty patients will be enrolled and treated with metformin 500 mg BD for a minimum of 7 days, until 2 days prior to surgery.
- Trial name
- Metformin 001 (NCT02978547)
- Testing
- Metformin Hydrochloride 500Mg Tablet
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Pancreas Cancer, Gastrointestinal Adenocarcinoma
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also…
- Trial name
- NCT04837833
- Testing
- ultrasound
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Ductal Adenocarcinoma (PDAC)
A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients
This is a phase II, multicenter, single arm study designed to evaluate the efficacy and safety of Inavolisib in second line pancreatic ductal adenocarcinoma（PDAC） patients.
- Trial name
- NCT07694973
- Testing
- Inavolisib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fudan University
Cancer Weight Loss
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients.
- Trial name
- NCT06937177
- Testing
- TCMCB07
- Where
- 26 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Endevica Bio
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreas Adenocarcinoma
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM).
- Conditions
- Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreas Adenocarcinoma, Peritoneal Metastases, Peritoneal Carcinomatosis
- Trial name
- DWI-PDAC (NCT05340569)
- Testing
- Whole-body diffusion-weighted magnetic resonance imaging
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Laval University
Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel.
- Conditions
- Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- BRAVE (NCT07714538)
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with…
- Trial name
- Carolyn-USA (NCT07049055)
- Testing
- E-EDV-D682, EDV-GC, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Engeneic Pty Limited
Carcinoma, Pancreatic Ductal
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis.
- Trial name
- PF-BARNA (NCT05489458)
- Testing
- Resection, No Resection
- Volunteers
- 100 people
- Sponsor
- BUSQUETS, JULI
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment
The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma.
- Trial name
- PERFECT (NCT07850336)
- Testing
- Endoscopic ultrasound-guided radiofrequency ablation
- Volunteers
- 56 people
- Sponsor
- Bojan Kovacevic
Solid Tumors
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- DAWN-303 (NCT07522073)
- Testing
- INCB161734, Investigator's choice of chemotherapy
- Where
- 230 sites in United States, Australia and 20 more
- Volunteers
- 588 people
- Sponsor
- Incyte Corporation
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
- Trial name
- NCT07020221
- Testing
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 616 people
- Sponsor
- Verastem, Inc.
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Adenocarcinoma Metastatic
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer.
- Trial name
- ParpVax2 (NCT06747845)
- Testing
- Niraparib, FOLFIRI, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Ductal Adenocarcinoma
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)
The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients.
- Trial name
- AIR-PANC (NCT05727319)
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- NHS Greater Glasgow and Clyde
Pancreatic Cancer, Chronic Pancreatitis
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma
The goal of this prospective multicenter observational study is to evaluate the diagnostic accuracy of blood-based protein biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC) in adults aged 18 years and older.
- Conditions
- Pancreatic Cancer, Chronic Pancreatitis, Intraductal Papillary Mucinous Neoplasm, Mucinous Cystic Neoplasm
- Trial name
- NCT07875582
- Testing
- Blood-Based Protein Biomarker Assessment
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer
Conduct a prospective study to assess the accuracy of a pancreatic cancer risk prediction model.
- Trial name
- PRO-TECT (NCT04883450)
- Testing
- Magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Kaiser Permanente